Abstract
Extracellular vesicles (EVs) are key mediators of intercellular communication, and those from the plasma of aged individuals are typically viewed as drivers of aging or even cancer. Here, we uncover a latent, potent antitumor capacity inherent to EVs derived from aged hosts. Specifically, we demonstrate that extracellular vesicles from the plasma of aged mice (A-EVs) exhibit robust tumor-suppressive activity in young tumor-bearing recipients. Mechanistically, A-EVs engage a dual mode of action: they directly induce senescence in cancer cells, enhancing their immunogenicity. More importantly, they concurrently activate non-tumor-specific bystander CD8⁺ T cells within the tumor microenvironment via cross-presentation of pathogen-derived antigens, thereby reshaping the immunosuppressive tumor microenvironment. This synergistic interplay potently reinvigorates antitumor immunity and sensitizes tumors to PD-L1 checkpoint blockade. Our findings establish A-EVs as a novel class of endogenous immunomodulators with broad therapeutic potential for cancer immunotherapy.
Full text
1,162 characters
· extracted from
oa-doi-fallback
· click to expand
Abstract
Extracellular vesicles (EVs) are key mediators of intercellular communication, and those from the plasma of aged individuals are typically viewed as drivers of aging or even cancer. Here, we uncover a latent, potent antitumor capacity inherent to EVs derived from aged hosts. Specifically, we demonstrate that extracellular vesicles from the plasma of aged mice (A-EVs) exhibit robust tumor-suppressive activity in young tumor-bearing recipients. Mechanistically, A-EVs engage a dual mode of action: they directly induce senescence in cancer cells, enhancing their immunogenicity. More importantly, they concurrently activate non-tumor-specific bystander CD8⁺ T cells within the tumor microenvironment via cross-presentation of pathogen-derived antigens, thereby reshaping the immunosuppressive tumor microenvironment. This synergistic interplay potently reinvigorates antitumor immunity and sensitizes tumors to PD-L1 checkpoint blockade. Our findings establish A-EVs as a novel class of endogenous immunomodulators with broad therapeutic potential for cancer immunotherapy.
Competing Interest Statement
The authors have declared no competing interest.
Text is read by the "Ask this paper" AI Q&A widget below.
Extraction quality varies by source — PMC NXML preserves structure
cleanly, OA-HTML may include some navigation residue, and OA-PDF can
have broken hyphenation. The publisher copy
(via DOI)
is the canonical version.